On July 22, 2025, the Korean government promulgated a partial amendment to the Korean Commercial Code (the “KCC”) following its passage at the National Assembly plenary session on July 3, 2025. This amendment package, long advocated by the Democratic Party and included among President Lee Jae-myung’s key campaign commitments, introduces a series of structural changes to Korean corporate governance.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jay Yang
Jay Yang - Pick Dawgz
Purchase any of the following packages to unlock premium picks. Package Hello Everyone! 4-1 night, can’t complain. We are definitely in the momentum! Who is with Jabombcapper?
April Musings 2025
It’s April. Filed my taxes. Pulled some weeds. Had some thoughts. I shared a ton on my podcast (listen on Spotify or iTunes). Here’s what’s been on my mind lately: Quick plug for AppSumo: we are giving away ChatGPT PRO for LIFE (yes, this is what they’re doing behind my back!) – it’s free. Go enter here. This tax season, I uploaded all my business tax docs to ChatGPT. Then I asked: “What am I missing?” Turns out, there were legit savings I hadn’t noticed.
Special Act on the Promotion of Offshore Wind Power Development and Distribution
On February 27, 2025, the Special Act on the Promotion of Offshore Wind Power Distribution and Industry Development (the “Special Act”) passed the plenary session of the Korean National Assembly and will be phased in gradually starting from the one year anniversary of its promulgation (the “Promulgation Date”).
해상풍력 보급 촉진 및 산업 육성에 관한 특별법
2025년 2월 27일, 「해상풍력 보급 촉진 및 산업 육성에 관한 특별법(안)」(이하 “법안”) 이 국회 본회의에서 최종 통과되었습니다. 해상풍력 발전사업에 공공주도 계획입지제 도를 도입하는 것을 골자로 하는 이번 법안은, 신규 풍황계측기 설치를 위한 공유수면 점용·사용허가 금지 등 일부 항목을 제외하고는 정부 이송 후 공포일로부터 1년이 경 과한 날로부터 시행됩니다. 향후 입지선정 및 인·허가 절차의 통합 및 간소화 등을 통 하여 사업의 불확실성이 완화되고 사업추진 소요기간이 단축될 것으로 기대됩니다. 1.주요 내용 (1) 정부 주도의 해상풍력발전사업 추진 1) 관련 정부기관의 신설 등(법안 제6조 내지 제11조) 국무총리 소속의 해상풍력발전위원회(이하 “위원회”)와 산업통상자원부 (이하 “산업부”) 내 해상풍력발전추진단이 신설됩니다.
From employee to 9-figure CEO whisperer
Meet my ex-CEO, Ayman Al-Abdullah. He joined AppSumo in 2016, and took the company from $5M to $70 million per year in revenue in only 6 years. Now, as a CEO coach, Ayman helps 7-figure CEOs get to 9-figure by working less. Here’s his story: Struggling entrepreneur Before joining AppSumo, Ayman had started a few businesses–but struggled to get them off the ground. “None of them had taken off,” he said, so he took a traditional 9-5 job.
What I Learned Working For Mark Zuckerberg
When I walked into the first floor of the Facebook building on University Avenue, in Palo Alto, I wasnât sure if I was in a frat house or a startup. There were cables falling from the ceilings, people running around and I was told to sit on a corner of someone elseâs desk. My new boss walked by me and said heâd find me after lunch.
The $500,000,000 meat stick company đ
Youâre crushing it as a commercial real estate broker. Your biggest deal was for $62M!! But then the housing market bottoms out and youâre forced to file for bankruptcy. What then? How do you respond? This was the dilemma Peter Maldonado (interestingly he has almost no social media) faced in March 2009.
Cal Newport changed my life
This week’s email is about Dr. Cal Newport: Full-time professor at Georgetown University Author of multiple best-selling books Has ZERO social media He also has a new book called ‘Slow Productivity’ about how to accomplish more (without burning out). It’s helping me think about sustainability and success. I’ve known Cal for several years – and I’m constantly amazed by his ability to think clearly and live life the “Cal Newport Way”. What does that mean?
The Anonymous and VERY happy $500 Million Man
Subscribe: Apple Podcasts Spotify Last week, I met someone with a net worth of $100m in cash. He has 0 social media, and you wouldn’t recognize him on the streets. He asked to stay anonymous, so for this post, let’s say his name is “John”. (He did drive up in a $250k sports car but inside the restaurant, he looked just like anyone else.) That’s the fascinating part about wealth, most of our stories and judgments about it are wrong.
He runs 9 businesses (with 0 employees)
Subscribe: Apple Podcasts Spotify Happy THURSDAY! Summer is finally here…here’s what’s been going on… ✅ What happened: YouTube. Filmed 3 videos, including a FIRE interview with Bill Perkins from Die with Zero. Can’t wait for you to see it. AppSumo. Announced the Tesla Cybertruck giveaway! 8 days left to enter. 48 Challenge Winner. Eli Moraru won my challenge from Tim Ferriss’s podcast. He visited Austin and I helped him with his startup. Mystery Hecto-Millionaire.
Top 5 lessons from 10,000 hours of my podcast
Subscribe: Apple Podcasts Spotify I’ve been doing the Noah Kagan Presents podcast (spotify – itunes) since 2017. Recently, we crossed 350+ episodes. In that time, I’ve interviewed SO many interesting people – including solopreneurs, billionaires, CEOS, athletes, moms, and celebrities. Here’s the BEST 5 lessons from 350 episodes of the podcast: In 1993, Kevin Kelly and his co-founders started Wired Magazine. At the time, they faced zero competition.
My skincare routine
I get asked all the time about my skincare routine. I’m 42. Started it at 25. Most of it – I credit my genetics (thanks Mom and Dad!!) So that’s tip #1: Choose better parents. Just kidding 😂 In all seriousness, skincare for guys doesn’t get talked about enough. Few like to say it out loud – but your health + face are one of the most important things in life.
How a 17-year-old got a $150,000+ job with me
It’s 2006. My buddy Dave McClure introduced me to a guy named Aaron who was building a product called mint.com (at the time it was called MyMint). I was super impressed. “This is the best product I’ve ever seen,” I told him. I noticed he was looking for a Director of Marketing – so I pitched him on why I would be a great fit. He laughed at me. “But you don’t know anything about marketing.” Fair point. So I spent the next week creating a 6-month marketing plan and launch strategy.
April Life Updates and Billionaires
Happy THURSDAY! A quick update on what’s been going on in my life since the launch of Million Dollar Weekend (then onto my billionaire lessons). What happened in March: Got MARRIED and baby due soon. 💍👶 Huge personal news. So grateful for my wife, Mafe. 🙏 Went on our honeymoon, an RV trip to sights like Zion National Park and Sedona. ⛰️ Reviews. Reached goal of 1000 book reviews for Million Dollar Weekend!! 🥳 THANK YOU. Continuing the momentum.
The ultimate 9-5 escape plan
This is from THIS episode – Spotify – iTunes Reid Hoffman (founder of LinkedIn) once said “Entrepreneurship is like jumping off a cliff and building a parachute as you go down.” 😅🪂 I don’t know about you, but that sounds stupid and dangerous. It’s much simpler to build a side hustle alongside your day job, hit your freedom number, and then jump ship if you want.
Brutally honest career advice to my younger self
Subscribe: Apple Podcasts Spotify I’m 42. The first 10 years of my career were a roller coaster of emotions: Rejected by MSFT Rejected by Google (2x) Fired by FB after 9 months Fired by mint .com after 10 months Built 20+ startups that didn’t work out But I’ve also: Built AppSumo to $100M/year in revenue Grew my YouTube channel to 1M+ subscribers And have interviewed 1% of the world’s billionaires In short… I’ve made A LOT of mistakes. But I’ve also learned a lot.
Form N-CSR Pender Real Estate Credi For: Dec 31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-CSR CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number 811-23806 Pender Real Estate Credit Fund (Exact name of registrant as specified in charter) c/o UMB Fund Services, Inc. 235 West Galena Street Milwaukee, WI 53212 (Address of Principal Executive Offices) Terrance P.
Cross Q&A: Role of Belantamab Mafodotin in MM
Transcript: Jack Khouri, MD: So, Greg, we seem like a big fan of this. Craig Cole, MD: I didn’t want to tell you. But the patients that I had on [the trial] are what make me a fan. The patients I had when we had to discontinue in November had to stop therapy and remain in very good, or even CRs [complete responses] for months and months. I think the longest one is a patient I still have from November when I discontinued, and she’s still in a CR.
DREAMM-3: Belantamab Mafodotin in Patients With Relapsed/Refractory MM
Transcript: Judy Schreiber, PhD, RN: We’ll go on to the next presentation, which will be Dr [Craig] Cole presenting on the DREAMM-3 study [NCT04162210]. Craig Cole, MD: Thanks, and I was just an investigator on the DREAMM-6 study [NCT03544281]. I want to thank everyone for inviting me, and Dr Weisel for sharing her slides with me. So belantamab mafodotin or Blenrep is a humanized anti-BCMA conjugated antibody.
Cross Q&A: Clinical Application of Ixa-Len-Dex for Patients With MM
Transcript: Craig Cole, MD: Faiz, where do you think you’d use a regimen like this? I think this was a French study done a few years ago. How do you think this fits into the landscape these days? Faiz Anwer, MD, FACP: I think this fits in with the more frail or [older] patients. A significant number of patients are not close to a major academic center. There’s a significant number of patients who don’t want to travel so frequently.
REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM
Contemporary Concepts Awareness Month Interactive Tools Nurse Practitioners/Physician's Assistants Partners Sponsored
Cross Q&A: Efficacy of CAR T-Cell Therapy in MM
Contemporary Concepts Awareness Month Interactive Tools Nurse Practitioners/Physician's Assistants Partners Sponsored
Treatment Considerations for Ponatinib in Patients With CML
Contemporary Concepts Awareness Month Interactive Tools Nurse Practitioners/Physician's Assistants Partners Sponsored
Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma
Transcript: Judy Schreiber, PhD, RN: Over to our Cleveland Clinic [team], if you have any comments or questions, or any statements you want to make related to this abstract, please feel free. Faiz Anwer, MD: I just have a question. …Who is the ideal patient eligible for this combination therapy?
CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM
Transcript: Judy Schreiber, PhD, RN: Let’s move on to the next abstract that will be presented by Dr Khouri, which is related to the CARTITUDE-4 study [NCT04181827]. Jack Khouri, MD: There are more exciting data on cilta-cel [ciltacabtagene autoleucel]. I’ll be presenting the results of the phase 3 CARTITUDE-4 study of cilta-cel vs standard of care with PVd [pomalidomide, bortezomib, dexamethasone] or DPd [daratumumab, pomalidomide, dexamethasone] in lenalidomide-refractory multiple myeloma [MM].
A Normalization Protocol Reduces Edge Effect in High-Throughput Analyses of Hydroxyurea Hypersensitivity in Fission Yeast
3.1.2. Growth Discrepancy of Colonies at Designated Positions on Agar Plates Next, we ask whether colony growth can be affected by locations within the media plate and, if so, whether that can confound the quantification and interpretation of strain hypersensitivity. We chose three strains—WT, Δcds1 and Δdad2 strains—that showed no, high and moderate sensitivity to HU, respectively, based on our previously reported serial dilution spotting assay [34] (C).
Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic
Contemporary Concepts Awareness Month Interactive Tools Nurse Practitioners/Physician's Assistants Partners Sponsored
Form N-CSRS Pender Real Estate Credi For: Jun 30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-CSR CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act File Number 811-23806 Pender Real Estate Credit Fund ____________________________________________ (Exact name of registrant as specified in charter) c/o UMB Fund Services, Inc. 235 West Galena Street Milwaukee, WI 53212 ____________________________________________ (Address of Principal Executive Offices) Terrance P.
International Journal of Molecular Sciences (Int. J. Mol. Sci.);
Targeted Covalent Inhibitors (TCIs), such as aspirin (Bufferin®), have a long history of more than 120 years, and most of them are synthetic small molecules. Instead, we have been developed larger "biomolecular" TCIs (bioTCIs) which can semi-permanently inhibit disease-related target proteins with little unwanted side-effects (Fig. A). Especially, as shown in Fig.
IJMS | Free Full-Text | bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements
3.2. Nucleotidic TCI: A Developing Modality Single-stranded DNA or RNA oligonucleotides form complex folded structures and a specific aptamer that binds to the desired target [81] can be identified by a repetitive screening of an aptamer library against the target by a process termed systematic evolution of ligands by exponential enrichment (SELEX) [82,83,84].
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Background Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of olutasidenib, as monotherapy or in combination with azacitidine, in patients with acute myeloid leukaemia or myelodysplastic syndrome, harbouring mutant IDH1.
An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a cancer with excellent long-term outcomes in most patients utilizing treatment with tyrosine kinase inhibitors (TKIs). A minority of patients are intolerant or resistant to multiple TKIs and have a more guarded prognosis. CML with T315I mutation is resistant to all first and second-generation TKIs. Ponatinib is a third-generation TKI that was specifically designed and developed to overcome resistance due to the T315I mutation.
Exploring the Psychosocial Impact on Parents of Adolescents Diagnosed With Hidradenitis Suppurativa: A Retrospective Claims-Based Analysis
Main Article Content Jay Yang Penn State College of Medicine Joslyn Kirby Penn State College of Medicine Steven Maczuga Penn State College of Medicine Keywords hidradenitis suppurativa, acne inversa, quality of life, depression, anxiety Abstract Background: Chronic conditions, such as hidradenitis suppurativa (HS), can have an immense impact on patient quality of life; however, less is known about the influence that these diseases may have on the parents of adolescent patients with HS.
Inhibition of thrombin activity by a covalent-binding aptamer and reversal by the complementary strand antidote
Inhibition of thrombin activity by a covalent-binding aptamer and reversal by the complementary strand antidote You have access to this article Please wait while we load your content... Something went wrong. Try again?
Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome
Jay Yang and Ali Gabali Blood 2019 133:2243; doi: https://doi.org/10.1182/blood.2018886564 A 65-year-old woman was diagnosed with myelodysplastic syndrome (MDS) with extra blasts-2 with 10% myeloblasts without any evidence of a mast cell disorder. She received azacitidine without response. Thirteen months after the initial diagnosis, she developed worsening pancytopenia and increasing (10%) circulating immature cells (panel A; Wright stain, original magnification ×500).
Taylor & Francis Online
Acute myeloid leukemia in older patients has historically had a dismal 10-15% long-term survival rate. Although patient frailty plays a role in this disappointing outcome, the primary driver of poor results remains the resistance of disease to current therapies. The optimal management of this difficult-to-treat disease should include a careful consideration of disease, patient and treatment factors.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jay
Contact Jay, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack